Altria Group Inc. Stock
€42.88
Your prediction
Altria Group Inc. Stock
Pros and Cons of Altria Group Inc. in the next few years
Pros
Cons
Performance of Altria Group Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Altria Group Inc. | 0.020% | -1.062% | 0.563% | 3.239% | 17.988% | 7.002% | -0.476% |
Philip Morris International | -0.480% | -0.672% | 1.166% | 5.735% | 11.402% | 11.876% | 34.156% |
Japan Tobacco Inc ADR | -1.610% | -1.587% | -1.587% | 25.888% | 7.826% | 57.962% | 27.179% |
British American Tobacco PLC | 0.240% | -4.045% | 1.331% | -5.130% | 8.899% | -13.483% | -11.200% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon a preliminary examination of Altria Group's financial statements, it appears that the company’s overall performance has experienced some fluctuation in the past few years. With a well-established presence in the Food and Tobacco industry, one would expect consistent growth and stability. However, a closer analysis of the company's financials may reveal a more comprehensive picture of its performance in the market.
Revenue Growth: Altria Group's total revenue has shown an increase over the past few years, moving from $20.84 billion in 2020 to $20.69 billion in 2021 and then to $20.69 billion in 2022. This suggests that the company continues to generate steady income, reflecting a strong presence within the industry.
Cash Flow from Operating Activities: The company has consistently generated positive cash flow from its operating activities over the past three years - $8.39 billion in 2020, $8.41 billion in 2021, and $8.256 billion in 2022. This reveals that Altria Group's core operations are generating significant cash, which can then be reinvested for sustainable growth or utilized for paying dividends and servicing debt.
Comments
News
![Altria Announces PMTA Submission for on! PLUS™ Nicotine Pouches:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWVvS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--645fa2c44c16c811b2f7f0d14bffcb0dc0baa1b0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ich_400.jpg?locale=us)
Altria Announces PMTA Submission for on! PLUS™ Nicotine Pouches
Today, Altria Group, Inc. (Altria) announces the submission of Premarket Tobacco Product Applications (PMTAs) to the U.S. Food and Drug Administration (FDA) for its innovative on! PLUS oral
![NJOY Receives First FDA Authorizations for Menthol E-Vapor Products:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWVvS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--645fa2c44c16c811b2f7f0d14bffcb0dc0baa1b0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ich_400.jpg?locale=us)
NJOY Receives First FDA Authorizations for Menthol E-Vapor Products
Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food and Drug Administration (FDA) issued marketing orders for NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod Menthol 5%, NJOY DAILY
![NJOY Submits Premarket Tobacco Product Applications to the FDA for NJOY ACE 2.0 Featuring Bluetooth®-enabled Access Restriction Technology:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWVvS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--645fa2c44c16c811b2f7f0d14bffcb0dc0baa1b0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ich_400.jpg?locale=us)
NJOY Submits Premarket Tobacco Product Applications to the FDA for NJOY ACE 2.0 Featuring Bluetooth®-enabled Access Restriction Technology
Today, NJOY, an Altria company, announces the submission of a supplemental Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) to commercialize and market